Wave Life Sciences is trading at $3.33, up 5.05%, as broader biotech strength offers a possible explanation; no clear company-specific catalyst was identified. - Biotech (XBI) is up 2.09%, amid industry M&A optimism and anticipation of cancer-vaccine data; this context does not establish the precise cause of Wave’s move. - Wave announced a virtual Research Day for November 4, with new platform data planned, and scheduled third-quarter results for October 27; both are upcoming events, not reported results.